Delcath Systems, Inc.
1100 Summer Street, 3rd Floor
Stamford
Connecticut
06905
United States
Tel: 203-323-8668
Fax: 203-961-0120
Website: http://www.delcath.com/
Email: jafoltz@aol.com
460 articles about Delcath Systems, Inc.
-
Delcath Systems Announces Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
4/30/2021
Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting to be held virtually June 4-8, 2021,
-
Delcath Systems, Inc. Announces Revised NICE Guidance for CHEMOSAT in the United KingdomRecommends Special Arrangement Designation Which Increases Reimbursement Options
4/21/2021
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that the United Kingdom’s (UK) National Institute for Health and Care Excellence (NICE), through the Interventional Procedures Advisory Committee, has updated its guidance for the Delcath CHEMOSAT®
-
Delcath Systems, Inc. Shares Additional Information Regarding FOCUS Trial Power Calculation20.1% Lower Bound of Preliminary ORR Analysis Exceeds Required 8.3% Threshold
3/31/2021
Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, provided additional information regarding the power calculation for the Phase 3 FOCUS trial of HEPZATO KIT in patients with liver dominant metastatic ocular melanoma.
-
Delcath Systems, Inc. Announces Positive Preliminary Results from Phase 3 FOCUS Trial of HEPZATO in Patients with Metastatic Ocular Melanoma
3/31/2021
- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced positive top-line preliminary results from the company's Phase 3 FOCUS trial of HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system)
-
Delcath Systems, Inc. Announces Fourth Quarter 2020 Results, Highlights Preliminary Positive FOCUS Trial Results; Conference Call Today at 8:00am Eastern Time
3/31/2021
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the fourth quarter ended December 31, 2020, and earlier today reported preliminary topline data. The company will host its quarterly call at 8:00am ET today, with a primary focus on discussing the preliminary top line data.
-
Delcath Systems Schedules Conference Call to Report 2020 Fourth Quarter Financial Results
3/24/2021
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on March 31, 2021 at 8:00 AM Eastern Time to discuss results for its fourth quarter ended December 31, 2020.
-
Delcath Systems to Participate at Upcoming Virtual Investor Conferences - Mar 08, 2021
3/8/2021
Delcath Systems, Inc., an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced that management will participate at these upcoming virtual investor conferences
-
Delcath Systems to Participate at Upcoming Virtual Investor Conferences
2/11/2021
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that management will participate at these upcoming virtual investor conferences:
-
Delcath Systems to Present at the H.C. Wainwright Virtual BioConnect Conference
1/11/2021
Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that management will present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference.
-
Delcath Systems Announces Completion of Underwritten Public Offering
12/11/2020
Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced the completion of an underwritten public offering of 1,679,031 shares of its common stock, including 219,004 shares sold pursuant to the full exercise of an option previously granted to the underwriters to purchase additional shares of common stock. All of the shares were offered by D
-
Delcath Systems Announces Pricing of Public Offering of Common Stock - Dec 09, 2020
12/9/2020
Delcath Systems, Inc., an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced the pricing of an underwritten public offering of 1,460,027 shares of its common stock at a public offering price of $13.25 per share.
-
Kevin Muir Joins Delcath Systems, Inc. as VP, Commercial Operations
12/7/2020
Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced Kevin Muir has joined the company as Vice President of Commercial Operations.
-
Delcath Systems, Inc. Announces Third Quarter 2020 ResultsConference Call Today at 8:30am Eastern Time
11/11/2020
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the third quarter ended September 30, 2020.
-
Delcath Systems, Inc. to Participate in Oppenheimer Fall MedTech Summit on Thursday, November 12, 2020
11/2/2020
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of primary and metastatic cancers, today announced management will participate in the Oppenheimer Fall MedTech Summit on Thursday, November 12, 2020.
-
Delcath Schedules Conference Call to Report 2020 Third Quarter Financial Results
11/2/2020
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of primary and metastatic cancers, today announced that it will host a conference call on November 11, 2020 at 8:30 AM Eastern Time to discuss results for its third quarter ended September 30, 2020. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Date: November
-
Delcath Systems Announces a KOL Call on November 5, 2020 to discuss the Results of a Prospective Phase II Study in Patients with Metastatic Ocular Melanoma
10/29/2020
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of primary and metastatic cancers, today announced that the Company will be hosting a Key Opinion Leader (KOL) call with Dr. Mark Burgmans, an Interventional Radiologist at the Leiden University Medical Center (LUMC) in The Netherlands, on Thursday, November 5, 2020, at 11:30am ET. Dr. Mark Burgmans will discuss results from a prospective ph
-
Delcath Strengthens Executive Team with Appointment of Gerard Michel as Chief Executive Officer
10/1/2020
Delcath Systems, Inc. (NASDAQ: DCTH) today announced that the Board of Directors appointed Gerard Michel as Chief Executive Officer, effective October 1, 2020
-
Delcath Systems, Inc. to Participate in Upcoming Virtual Investor Conferences
9/10/2020
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today announced management will participate in two upcoming virtual investor conferences
-
Delcath to Present at the LD Micro 500 Virtual Investor Conference on Tuesday, September 1, 2020 at 3:00pm ET
8/25/2020
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today announced management will present at the LD Micro 500 Virtual Conference Tuesday, September 01, 2020 3:00 PM ET. A live webcast of the presentation will be available to the public at https://www.webcaster4.com/Webcast/Page/2019/36399 . The webcast will be archived for 90 days following the liv
-
Delcath Systems, Inc. Announces Second Quarter 2020 Results
8/13/2020
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announces financial results for the quarter ended June 30, 2020, and will host an earnings call on August 13, 2020 at 4:30 p.m.